GPCRs: The most promiscuous druggable receptor of the mankind
- PMID: 34194261
- PMCID: PMC8233523
- DOI: 10.1016/j.jsps.2021.04.015
GPCRs: The most promiscuous druggable receptor of the mankind
Abstract
All physiological events in living organisms originated as specific chemical/biochemical signals on the cell surface and transmitted into the cytoplasm. This signal is translated within milliseconds-hours to a specific and unique order required to maintain optimum performance and homeostasis of living organisms. Examples of daily biological functions include neuronal communication and neurotransmission in the process of learning and memory, secretion (hormones, sweat, and saliva), muscle contraction, cellular growth, differentiation and migration during wound healing, and immunity to fight infections. Among the different transducers for such life-dependent signals is the large family of G protein-coupled receptors (GPCRs). GPCRs constitute roughly 800 genes, corresponding to 2% of the human genome. While GPCRs control a plethora of pathophysiological disorders, only approximately one-third of GPCR families have been deorphanized and characterized. Recent drug data show that around 40% of the recommended drugs available in the market target mainly GPCRs. In this review, we presented how such system signals, either through G protein or via other players, independent of G protein, function within the biological system. We also discussed drugs in the market or clinical trials targeting mainly GPCRs in various diseases, including cancer.
Keywords: AC, Adenylyl Cyclase; Arrestin; CCR, Chemokine Receptor; COX, Cyclooxygenase; DAG, Diacylglycerol; Drugs; ERK, Extracellular signal-Regulated Kinase; G proteins; GIP, Gastric Inhibitory Peptide; GLP1R, Glucagon-Like Peptide-1 Receptor; GPCR; GRKs; GRKs, G protein-coupled Receptor Kinases; Heterodimerization; IP3, Inositol 1,4,5-triphosphate; MAPK, Mitogen-Activated Protein Kinase; NMDA, N-Methyl D-Aspartate; Nbs, Nanobodies; PAR-1, Protease Activated Receptor 1; PIP2, Phosphatidylinositol-4,5-bisphosphate; PKA, Protein Kinase A; Signaling; cAMP, cyclic AMP.
© 2021 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
References
-
- Ahmed, A.A.M.A., 2019. Antiplatelet drug management. In: Patient Blood Management in Cardiac Surgery. Springer, 51–60.
-
- Akhter S.A., D'Souza K.M., Petrashevskaya N.N., Mialet-Perez J., Liggett S.B. Myocardial beta1-adrenergic receptor polymorphisms affect functional recovery after ischemic injury. Am. J. Physiol. Heart Circ. Physiol. 2006;290:H1427–H1432. - PubMed
-
- Alvarez-Curto E., Inoue A., Jenkins L., Raihan S.Z., Prihandoko R., Tobin A.B., Milligan G. Targeted elimination of G proteins and arrestins defines their specific contributions to both intensity and duration of G Protein-coupled Receptor Signaling. J. Biol. Chem. 2016;291:27147–27159. - PMC - PubMed
-
- Andrews G., Jones C., Wreggett K.A. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Mol. Pharmacol. 2008;73:855–867. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
